# Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients

> **NCT03458728** · PHASE1,PHASE2 · TERMINATED · sponsor: **Bayer** · enrollment: 31 (actual)

## Conditions studied

- Relapsed or Refractory Solid Tumors or Lymphoma in Children
- Neuroblastoma
- Osteosarcoma
- Rhabdomyosarcoma
- Ewing Sarcoma

## Interventions

- **DRUG:** Copanlisib (BAY806946)

## Key facts

- **NCT ID:** NCT03458728
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-04-30
- **Primary completion:** 2023-02-01
- **Final completion:** 2023-02-01
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** no anticipated benefit over available standard therapies
- **Last updated:** 2023-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03458728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03458728, "Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03458728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*